INTRODUCTION
The emergence of a new method for diagnosing infertility, such as the assessment of sperm DNA fragmentation, requires new treatment approaches. Existing standard selection methods in ART programs are not able to effectively separate gametes with damaged genetic material. Against this background, the emergence of microfluidic chip technology, which makes it possible to most accurately model the barrier function of the female reproductive system and minimize the impact of damaging factors, seems promising as a possible method of sperm selection in patients with a high level of DNA fragmentation.
THE AIM OF THE STUDY
To assess the effect of the use of microfluidic chips on the effectiveness of ART programs in patients with a high level of DNA fragmentation.
MATERIAL AND METHODS
The prospective study involved 31 married couples. The inclusion criteria were: the age of the man is less than 50 years, the age of the woman is under 35 years, the male factor of infertility associated with a high level of SDF (>30%), an unsuccessful ART program in anamnesis. All study participants underwent two consecutive ICSI programs. During the first program, sperm selection was carried out using the standard method of density gradient centrifugation. In the second ICSI, microfluidic chips were used to select male gametes. Subsequently, the results of the embryological and clinical stages were compared between the programs carried out.
OUTCOMES
The use of microfluidic chips made it possible to significantly increase the fertilization rate (88.42% vs. 81.45%; p <0.05), the proportion of blastocysts obtained (39.48% vs. 22.06%, p <0.00001) and the cumulative pregnancy rate (38.71% vs. 16.13%; p= 0.020) compared to sperm selection by density gradient centrifugation.
CONCLUSION
The use of microfluidic chips in ART programs has significantly improved both embryological and clinical results of treatment of patients with a high level of DNA fragmentation in the ejaculate. It is necessary to conduct additional studies in order to confirm the identified patterns and make a decision on expanding the use of microfluidic technologies in medical practice.